Connect with us

Cannabis News

Massachusetts Attorney General’s Office Is Receiving Complaints About Anti-Marijuana Initiative Petitioners’ Tactics

Published

6 months ago

on

The Massachusetts attorney general’s office has confirmed that it is receiving complaints from the public about applicants for a 2026 ballot initiative aimed at rolling back the state’s marijuana legalization law, with a growing number of people alleging that signature gatherers are selling misleading information about the proposal.

A staffer in Massachusetts Attorney General (D) Andrea Campbell’s office told Marijuana Moment on Friday that while they can confirm they have received those complaints, they are not at liberty to discuss whether the matter is actively being investigated.

The office “has received complaints about this matter, but we cannot confirm, deny or comment on any investigation,” they said.

“Every application has a summary of the Attorney General’s bill printed at the top,” the staffer said. “We strongly encourage voters to read the summary of any bill carefully before deciding whether to sign it.”

Massachusetts Cannabis Business Association (MCBA) David O’Brien on Friday openly accused the campaign behind the repeal initiative, the Coalition for a Healthy Massachusetts, of hiring paid petitioners to use “trickery tactics” to add signatures.

“These out-of-state groups are collecting signatures from state to state and it’s clear that they’re having trouble here in Massachusetts finding people who want to repeal our very effective cannabis laws and kill our successful cannabis industry,” O’Brien said. “This is voter fraud that people should report to their town hall.”

The Marihuana Moment campaign was reached for comment, but a representative was not immediately available.

According to the MCBA, reports of deceptive signature-gathering tactics are widespread, with paid petitioners using fake letters on other ballot measures, such as affordable housing and same-day voter registration.

A Reddit post earlier this week appeared to show such tactics, with two petitioners sitting at a table with signs about housing and voter registration, but the poster said they were collecting signatures for a marijuana repeal initiative.

Bait and switch signature request
according tou/yanki2del in the yearmassachusetts

MCBA said in a press release that “other fraudulent messages reported by voters claimed the ballot question would strengthen fentanyl testing requirements for marijuana and expand buffer zones between dispensaries and schools.”

Voters in Massachusetts have sounded the alarm about the state of social media, sharing their experiences with applicants who appear to be misrepresenting marijuana initiatives, in some cases as a way to protect young people from being criminalized for possessing cannabis.

“Just wanted to give a heads up to *anyone* interested in the legal status of cannabis in Massachusetts. While shopping this morning I was presented with a ‘legislation to protect minors from arrest with 2oz of cannabis or less’ signature form,” a post on Reddit last week. he says. “I refused to sign after reading the first line that stated that the current laws on cannabis would be repealed.”

Until then, the Prosecutor’s Office has stressed the importance of reading its summary, which should go at the top of the signature form, before signing any request. Chief Prosecutor cleared the signature collection campaign, with a summary of the petition, last month.

Another Reddit post shared on Wednesday was by a user he said “They joined a couple of interns at the grocery store who were gathering signatures for a ballot initiative to end the sale of recreational marijuana,” and “people misrepresenting what the ballot question really is when asking for signatures.”

Another post describes the user’s experience with a petition that said the initiative was “to make sure kids didn’t go to jail for minor marijuana offenses.”

“The big sign behind it read DARE to keep kids off drugs. When I read it, it was clearly a petition to recriminalize marijuana. Be careful and know what you’re signing!” they he said.

There are numerous responses to the posts, with others telling similar stories and sharing tips on how to report illegal election activity.

“Voters heading to the polls on Election Day next Tuesday, November 4th should expect signature gatherers to be at polling places across the state,” said Meg Sanders, CEO of Canna Provisions. “Know what you’re signing! Take your time and read the application language. If the collector doesn’t say what it says, don’t sign.”

The marijuana repeal campaign, for its part, said as much this month They are “on the way” to get enough signatures to put the initiative on the ballot. They are working to send 100,000 signatures by December 3rd.

When the Attorney General’s Office completed its review of 50 proposed ballot measures for 2026, it certified two versions of the proposed recriminalization campaign.

Both would eliminate the state’s adult commercial use market, maintain patient access under the medical cannabis program and continue to allow legal possession of an ounce of recreational marijuana. “Version A” contains language that would also limit THC content for medical marijuana, while “Version B” omits that policy.

The campaign continues this latest initiative without a cap.

Under the initiative, called the “Restoration of Sensible Marijuana Policy Act,” adults over the age of 21 can still possess up to one ounce of cannabis, of which only five grams can be the product of concentrated marijuana.

Possession of more than one ounce but less than two ounces would effectively be decriminalized, with violators facing a $100 fine. Adults can also continue to gift cannabis to each other without payment.

But provisions of the state’s voter-approved marijuana law that allow commercial cannabis sellers and adults to access regulated products would be repealed under the proposal.

The right of adults to cultivate cannabis at home would also be repealed.

Meanwhile, the head of Massachusetts’ marijuana regulatory agency recently suggested measures to effectively recriminalize the sale of recreational cannabis. dangerous tax revenues being used to support substance abuse treatment efforts and other public programs.

If enough signatures are validated from the initial submissions, the proposal will go before the legislature, and lawmakers will have until May 6 to pass the law or propose a replacement. If they don’t, organizers will need to collect an additional 12,429 valid voter signatures to put the measure on the ballot.

Whether the cannabis measures make the cut remains to be seen. Voters approved legalization on the 2016 ballot, and sales began two years later. And in the last decade the market has evolved and expanded. In August, Massachusetts officials reported more than $8 billion in adult marijuana sales.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Regulators are also working to finalize the rules allow a new type of lounge license to consume cannabisthey hope to finish by October.

Separately, in May the CCC launched an online platform helping people find work, on-the-job training and networking opportunities in the state’s legal cannabis industry.

The House Joint Committee on Cannabis Policy approved the bills in August protect employment for marijuana users and expand the state’s medical cannabis programin part by adding post-traumatic stress disorder (PTSD) and opioid use disorder to the list of qualifying conditions.

State legislators have also been pondering imposing stricter restrictions on intoxicating hemp-derived products and a plan allowing individual entities to control a greater number of cannabis establishments.

Also in Massachusetts Legislators working on state budgets butted heads with CCC officialswho said critical technology improvements can’t be made without more money from the legislature.

Meanwhile, Massachusetts lawmakers have just passed a bill establishing a pilot program for the regulated therapeutic use of psychedelics. And two committees have held hearings to discuss additional measures related to psilocybin.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Cannabis operators report mixed results as rescheduling reshapes the financial outlook

Published

10 hours ago

on

May 14, 2026

By

The rescheduling came mid-quarter and rewrote the tax math for each medical sales operator, but the underlying revenue picture remained uneven in early 2026, with acquisitions driven at one end of the scale and continued top-line compression at the other.

Vireo Growth: Back on $106 million deal
Vireo Growth Inc. reported Q1 GAAP revenue of $106.2 million, up 333.5% year-over-year, driven almost entirely by recent acquisitions rather than organic growth. The company completed the Schwazze acquisition in March, adding 45 dispensaries and two manufacturing facilities in Colorado and New Mexico. At the end of the quarter, it closed Eaze and Hawthorne Gardening, FLUENT Corp. announced an acquisition agreement and executed a California dispensary joint venture with Glass House Brands. Treating all acquisitions as closed on January 1, 2025 on a pro forma basis, revenue was $210.2 million and adjusted EBITDA was $42.2 million. The company ended the quarter with $137.8 million in cash.

John Mazarakis, CEO of Vireo, said: “Performance in the first quarter met our expectations and we are excited to welcome Schwazze, Eaze and Hawthorne to Vireo. We are focused on integration and optimization across the platform, while remaining opportunistic regarding growth opportunities associated with further acquisitions.”

Cresco Labs: $151 million, 280E relief and Texas license
Cresco Labs reported Q1 revenue of $151 million, down from $165.8 million in Q1 2025. Adjusted gross margin was 50.7% and adjusted EBITDA margin of $33 million was 21.7%. Cash at the end of the quarter was $67 million against a $310 million secured term loan. The company was conditionally granted a Texas Compassionate Use Program license after the quarter ended and opened two new dispensaries in Ohio.

Management said, “Moving the state’s legal medical cannabis from Schedule I to Schedule III is the most impactful reform this industry has seen, and it validates the work we’ve been executing for years. We’ve built the operational foundation and balance sheet discipline to reap the immediate benefits of rescheduling, and position Cresco to take advantage of the broader path to normalization.”

Jushi Holdings: 4% growth, 460 basis point margin expansion
Jushi Holdings reported first-quarter revenue of $66.4 million, up 4% year-over-year, with gross profit margin up 460 basis points to 45%. Adjusted EBITDA was $11.4 million, up 17.2%. The margin improvement was driven by higher production volumes in Ohio, Massachusetts and Pennsylvania and the performance of grower processors. Jushi brand products accounted for 58% of retail revenue in vertical markets. The company refinanced $132.3 million in debt during the quarter, providing $160 million in new debt through 2029.

Jim Cacioppo, president and CEO, said: “The recent scheduling of state-licensed medical marijuana for Schedule III is an important milestone for the industry, eliminating 280E tax limitations for medical operations and supporting a more favorable long-term operating environment.” Medical sales accounted for about 60% of Jushi’s 2025 revenue, making this material relief.

iAnthus Capital: Revenue falls to $33.5 million
iAnthus Capital reported first-quarter revenue of $33.5 million, down $4.6 million from 2025’s first quarter. Gross margin was 47.5%, up 477 basis points from the 2025 quarter. The company did not provide a management comment in the press release.

Country farms: international export record, fourth consecutive quarter of net income
Village Farms International reported first quarter consolidated net sales of $50.2 million, up 27% year-over-year, with net income of $2.9 million and adjusted EBITDA of $9.9 million, up 118% year-over-year. International export sales increased 171% to a record $14.6 million, driven by demand for EU-GMP compliant products in Germany. Pure Sunfarms had the top Canadian market share in dried flowers for the 15th consecutive month. The company started planting the first half of its Delta 2 greenhouse expansion and expects its Phase II facility in the Netherlands to reach full capacity by the end of 2026, which would quadruple Dutch production.

Michael DeGiglio, President and CEO, said: “Our first quarter results reflect a strong start to the year and continued momentum in our largest markets, with adjusted EBITDA growth of 118% year-over-year, significantly outpacing revenue growth of 27%, driven by our international business and continued leadership in Canada.

Cronos Group: Record revenue, $822 million in cash
Cronos Group reported Q1 net income of $45.2 million, up 40% year-over-year and a record quarter, with net income of $15.7 million and adjusted EBITDA of $5.1 million. Israel led growth PEACE NATURALS grew 53% for ninth consecutive record quarter. In Canada, the Spinach brand took first place in vapes with a 9.8% share of the national market, and maintained its top spot in edibles at 20.8%. The company ended the quarter with $821.9 million in cash and authorized a new $50 million stock repurchase program. The deadline to close the acquisition of CanAdelaar, one of the ten licensed growers in the Dutch Controlled Cannabis Supply Chain Experiment, has been extended to September 9, 2026 to allow time for regulatory approvals.

Mike Gorenstein, chairman, president and CEO, said, “Cronos achieved net earnings and gross profit in the first quarter as we continue to execute against our unlimited product strategy and the additional supply from Cronos GrowCo’s expansion fuels the next phase of our growth.”

Org chart: Revenue down 9%, Sanity Group acquisition closes after quarter
Organigram Global reported fiscal second quarter net income of $59.8 million, down 9% year-over-year, with adjusted EBITDA of $0.9 million, down 82%. Lower vape and pre-infusion sales drove the decline, along with a $5.8 billion dent in the U.S. hemp business. The company achieved a record quarterly harvest of over 32,000kg at its Moncton facility, up 56% year-on-year, and launched 10 SKUs in Australia targeting over 4,000 pharmacies. At the end of the quarter, Organigram acquired Sanity Group, one of Germany’s leading cannabis companies, and updated its 2026 guidance to net revenue of more than $350 million.

James Yamanaka, CEO, said: “Q2 reflected our poor performance in vaporizers and temporary challenges in pre-infusion production, compounded by slower industry growth. We have acted quickly to address these issues, and the operational changes and product improvements we have implemented are already beginning to stabilize performance.”

Greg Guyatt, Chief Financial Officer, said: “The financial impact of the competitive and operational challenges encountered earlier in fiscal 2026 is believed to have materialized in the first half of the year, and we are now beginning to stabilize performance. We expect to resume a trajectory of margin expansion and improved profitability during the second half of the year, supported by positive revenue and international sales growth. The Sanity Group.”

Continue Reading

Cannabis News

Medical Marijuana Helps Pain Patients Reduce Use Of Opioids, New Study Shows

Published

10 hours ago

on

May 14, 2026

By

As opioids continue to cause overdose deaths, a new study suggests that making medical cannabis available and affordable could help patients reduce their use of prescription painkillers.

“Although cannabis has historically been characterized as a potential ‘gateway drug,’ it may also serve as a harm reduction tool for some patients seeking to reduce their reliance on higher-risk opioid medications,” researchers at the University of Pennsylvania Perelman School of Medicine found.

The study, a prospective observational trial at the Hospital of the University of Pennsylvania, followed 29 adults over five months. All had been living with chronic pain for years—an average of 11 years—and were already taking opioid medications, but struggled to taper off of them despite other treatments.

The study is unique in its focus on cost as a factor in access to medical marijuana, with the researchers describing their work as “the first prospective observational study evaluating medical cannabis as an alternative to opioids in a setting where cost was removed as a major barrier.”

Participants were recruited from a university outpatient chronic pain clinic and then completed monthly pain assessments using the Numeric Pain Rating Scale (NRS). The researchers measured daily opioid use, measured in milligrams of morphine equivalents (MME).

“Seven patients (24%) were able to completely discontinue opioid therapy at the end of the study, five of whom did so by the second month. Pain levels also decreased over time,” the authors wrote.

Notably, “there was a statistically significant reduction in mean pain scores experienced over the five-month study period,” says the paper published in the Cureus Journal of Medical Science.

“There was also a reduction in average opioid consumption of about 32 MME per day, which remained the same throughout the follow-up. In addition, seven patients were able to completely discontinue opioid therapy during the study.”

“Mean daily opioid consumption decreased from 46.8 MME/day at baseline to 16.2 MME/day at one month and remained low during the five-month follow-up period,” the researchers found.

What set the new study apart was not just the inclusion of medical cannabis, but the deliberate removal of cost as a barrier. Participants “consistently identified cost as a major barrier to initiating medical cannabis” before enrolling in the study, the document says.

Noting the novelty of the study, they added their hypothesis: “Improving access to medical cannabis will allow a subset of patients, especially those with a high cost barrier, to reduce or discontinue opioid use while maintaining adequate pain control.”

“These results suggest that medical cannabis may be a useful adjunctive therapy to reduce opioid use, relieve chronic pain, and improve health-related quality of life,” they concluded.

“The findings of this study add to the body of literature supporting the safety profile and potential therapeutic role of cannabis.”

The studies the authors are cautious in their conclusions, warning of limitations and the need for further research. “The sample size was small and derived from a single clinical site, and there was no control group.” And because “patients self-titrate cannabis products, leading to variability in dosage and frequency of use,” the findings are not standardized.

But the authors concluded that “when used under appropriate medical supervision, medical cannabis may be an effective adjunctive strategy to reduce opioid use among patients receiving long-term opioid therapy.”

This study follows a Recent research shows that using medical marijuana helps people reduce their use of other drugs, including opioids.sleep aids and antidepressants. They also experience fewer negative side effects after switching from prescription drugs to cannabis, according to a study involving more than 3,500 patients.

It also comes from behind President Donald Trump says marijuana ‘can make people feel a lot better’ and serves as a “substitute for addictive and potentially lethal opioids.”

Last month, the Trump administration announced it moving forward with federal reclassification of marijuana medicinal cannabis is classified under Schedule I to III of the Controlled Substances Act.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Livermore Falls debates cannabis licensing fees

Published

1 day ago

on

May 13, 2026

By











Existing medical cannabis licensing fees will be temporarily applied to recreational marijuana businesses, the Select Committee decided on May 5. Board members agreed 4-1 to the temporary change, as long as officials say the fees are higher than necessary and accurately reflect the town’s oversight costs.

Bryce Cobb, Livermore Falls’ code enforcement officer, plumbing inspector, health officer and E-911 dispatcher, said voters approved the amended cannabis ordinance on April 28. Cobb said the amended ordinance allows recreational marijuana businesses and the next step was to establish a fee schedule. Recreational cannabis businesses operating in town would require local licensing approval under the ordinance.

Asked if he had fee schedules from other towns to compare, Cobb said he did not. Additionally, the town’s fee schedule specifically mentions medicinal cannabis.

“So it could be medical and adult use,” Cobb said when discussing whether the existing fee structure could apply to recreational businesses.

Read more at Sun Magazine










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media